Genprex to Present Diabetes Gene Therapy at Symposium
Genprex's Pier-Anne Lachance, Ph.D., will present on the company's parallel diabetes gene delivery programs at a virtual symposium.
Updated on Nov. 11, 2026 in Diabetes
Genprex, Inc. announced that Pier-Anne Lachance, Ph.D., its Senior Director of Quality Control & Product Development, will present at Drug Discovery News' Future of Cell and Gene Therapy Symposium on November 17-18, 2026. The virtual event is scheduled for the company's presentation on diabetes gene therapy.
Why it matters
The presentation will describe two distinct gene delivery approaches for Genprex's diabetes program, both currently in preclinical development. Evaluating both approaches is intended to help inform future development decisions for the program.
The announcement is a company-issued notice of a scheduled virtual presentation, with the symposium lasting two days. Preclinical efficacy and the eventual choice between the AAV-based and lipid-based approaches remain unreported.
The players
Genprex, Inc.
A clinical-stage biotechnology company listed on NASDAQ under the symbol GNPX, developing gene therapies for cancer and diabetes.
Pier-Anne Lachance, Ph.D.
Genprex's Senior Director of Quality Control & Product Development, who is presenting the company's diabetes gene therapy work.
The details
Lachance's talk, titled "Building the Future of Diabetes Gene Therapy: Lessons from Parallel AAV and Lipid-Based Development Programs," will cover Genprex's AAV-based approach, designed to deliver the Pdx1 and MafA genes to the pancreas, and its evaluation of a non-viral lipid-based delivery method. The company, a clinical-stage biotechnology firm listed on NASDAQ as GNPX, is also evaluating its lead oncology product Reqorsa in the Acclaim-1 and Acclaim-3 trials.
Timeline
November 11, 2026: Genprex announces Lachance's upcoming presentation.
November 17-18, 2026: The Future of Cell and Gene Therapy Symposium takes place virtually.
Big Picture
The talk is one of the program's contributions on gene therapy development at the Drug Discovery News' Future of Cell and Gene Therapy Symposium, reflecting the symposium's focus on advancing cell and gene therapy approaches. It sits within the broader effort to develop non-viral and viral delivery methods for chronic metabolic disease.
For people living with diabetes, these preclinical gene therapy efforts remain experimental and are not yet available as treatment. Any eventual therapy would depend on future clinical trial results that the presentation does not report.
The takeaway
Diabetes gene therapy remains in early preclinical development, so readers should watch for clinical data before drawing conclusions about treatment options. Parallel delivery approaches show companies are still testing which method is most viable.
What happens next
Genprex's presentation is scheduled during the November 17-18, 2026 symposium.
Further reading
Explore more on Diabetes research and treatment developments.
More information
Access Genprex website presentation recordings for the company's presentation materials.
Source note: This article includes information reported by Star Local.
